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Abstract
Background: During surgery for endometrial cancer, a pelvic lymphadenectomy with or without para-aortic
lymphadenectomy is performed at least in patients with risk factors (stage I, grading 2 and/or histological subtypes
with higher risk of lymphatic spread), and is hence recommended by the International Federation of Obstetrics and
Gynecology (FIGO). Although lymph node metastases are important prognostic parameters, it has been
contentious whether a pelvic lymph node dissection itself has a prognostic impact in the treatment of endometrial
cancer, especially in endometrioid adenocarcinoma. Therefore, this study evaluated whether lymphadenectomy has
a prognostic impact in patients with endometrioid adenocarcinoma.
Methods: The benefits of lymphadenectomy were examined in 214 patients with a histological diagnosis of
endometrial adenocarcinoma. Tumour characteristics were analysed with respect to the surgical and pathological
stage.
Results: Of the 214 patients with endometrial adenocarcinoma, 171 (79.9%) were classified as FIGO stage I, 15
(7.0%) FIGO stage II, 21 (9.8%) FIGO stage III and 7 (3.3%) FIGO stage IV. One hundred and thirty four (62.6%) of the
patients had a histological grade 1 tumour, while 56 (26.2%) and 24 (11.2%) had a histological grade 2 or grade 3
tumour, respectively. Lymphadenectomy was performed in 151 (70.6%) patients. Only 11 (5.1%) patients showed
metastatic disease in the lymph nodes. The performance of a lymphadenectomy resulted in significantly increased
cause-specific and overall survival, while progression-free survival was not affected by this operative procedure.
Conclusions: The performance of an operative lymphadenectomy resulted in better survival of patients with
endometrioid adenocarcinoma. This increase was significant for cause-specific and overall survival, while there was
a tendency only towards increased progression-free survival. Therefore, even in endometrioid adenocarcinoma, a
pelvic and/or para-aortic lymphadenectomy should be performed.
Background
Endometrial cancer is the most common female pelvic
malignancy in industrial countries, with an estimated
annual incidence of 15-20 per 100,000 women. The life-
time risk of developing endometrial cancer is approxi-
mately 2.5%, while the lifetime probability of dying from
this cancer is estimated at 0.52% [1,2]. In 1988, the
International Federation of Gynecology and Obstetrics
(FIGO) established a new pathological and surgical sta-
ging system for endometrial cancer. The surgical staging
includes an explorative laparatomy with radical hyster-
ectomy and bilateral salpingo-oophorectomy, peritoneal
washing, and pelvic and para-aortic lymph node sam-
pling [3]. However, no specifications regarding the type
and extent of pelvic lymph node dissection have been
established. The extent (sampling or dissection) and per-
formance of additional para-aortic sampling varies from
surgeon to surgeon [4]. Particularly in patients with a
low risk for lymph node metastases (due to superficial
depth of invasion, small size of tumour and low tumour
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any medium, provided the original work is properly cited.grade) a routine lymph node dissection is often not per-
formed. Moreover, substantial co-morbidities such as
obesity or old age are considered contraindications to a
full pelvic and/or para-aortic lymphadenectomy. There-
fore, pelvic and/or para-aortic lymph node dissection
has been a subject of continuous debate.
In 1987 and 1991, two large staging trials identified
important prognostic factors in endometrial carcinoma,
primarily age, race and endocrine status [5,6]. Uterine
factors included histological cell type, tumour grade,
depth of myometrial invasion, occult extension of the
cervix and vascular space invasion. Additionally, extrau-
terine prognostic factors were defined as adnexal metas-
tasis, other extrauterinal spread, positive peritoneal
cytology, pelvic lymph node metastases, and para-aortic
involvement [5,6]. However, it was not assessed whether
a lymphadenectomy itself has prognostic value in
patients with endometrial cancer. Since then, a few stu-
dies have addressed this issue, but the results and con-
clusions have been rather inconsistent. In particular, the
value of lymphadenectomy in early stage cases is still
controversial [7-9]. Some recent studies have investi-
gated the impact of the extent of lymph node removal
in surgical treatment of endometrial cancer. The results
demonstrated an impact on survival for patients with a
higher number of dislodged lymph nodes, especially in
cases showing high-risk clear-cell or serous-papillary
histology [10-12]. In 2007, a retrospective analysis by
the Surveillance Epidemiology and End Results program
(SEER) in the U.S.A. reviewed a large population data-
base and concluded that lymphadenectomy results in
improved survival of patients with endometrial cancer
[13]. However, in a recent prospective study, there was
no evidence of benefit from pelvic lymphadenectomy in
terms of overall or recurrence-free survival in women
with early endometrial cancer [14].
The aim of this study was to evaluate the outcome of
patients with endometrioid adenocarcinoma, histologi-
cally the most common type of endometrial cancer
(approximately 80% of all endometrial cancers) [15],
with regard to performance of a lymphadenectomy in a
well-characterized cohort population. The study also
aimed to assess whether performance of a lymph node
dissection constitutes an independent prognostic factor
in this patient group. Finally, we examined whether per-
formance of a lymphadenectomy constitutes a prognos-
tic parameter in early-stage compared to late-stage
disease.
Methods
For this retrospective study, we reviewed pathological
and surgical records of 308 patients operated on
between 1990 and 2002 in the 1
st Department of Obste-
trics and Gynaecology, Campus Innenstadt, Ludwig-
Maximilians-University Munich. This patient group had
been previously well characterised and several prognos-
tic markers had been evaluated [16,17]. All patients had
a preoperative ultrasound imaging examination and
underwent hysterectomy, bilateral salpingo-ophorect-
omy, and optional pelvic and/or para-aortic lymph node
sampling. The decision to perform lymphadenectomy
was made by the surgeon and was influenced by the
patients’ characteristics (histological report of abrasion,
progress of cancer, age, obesity and further comorbid-
ities) as well as rapid intraoperative histological evalua-
tion. Pathological reports were examined for histologic
type, FIGO stage, grade, depth of myometrial invasion
and lymph node status. Pathological stage, histological
subtype and lymph node status were defined for each
surgical specimen according to the 1988 FIGO criteria
[3]. Histological classification was made according to the
World Health Organization (WHO) system as well-dif-
ferentiated (G1), moderately-differentiated (G2) and
poorly-differentiated (G3). Only patients with endome-
trioid adenocarcinoma histology were included. Exclu-
sion criteria were serous-papillary, clear-cell, pure
squamous or mesenchymal histology, or mixed histology
and pre-operative radiation.
Patient data were supplemented with medical records
from the oncology archives of our hospital, and the
Munich tumour registry. The Munich tumour registry
systematically collects baseline data, including demo-
graphic data, diagnosis, additional diseases (e.g., obesity,
diabetes or hypertension) and treatment information for
all cancer patients who are diagnosed or treated in the
1
st Department of Obstetrics and Gynaecology. Auto-
mated records and, when available, charts for each
patient were reviewed to verify diagnosis and the pre-
sence or absence of radiologic or pathological evidence
of disease recurrence. Patient data were analyzed anon-
ymously. For all cases of recurrence there was radiologic
evidence or biopsy-proven progression of disease. Only
the records of patients who died of disease were consid-
ered to be uncensored; the records of all patients who
were alive at follow-up or who did not die of disease (or
a related cause) were considered to be censored. Addi-
tionally, those cases where the exact cause of death was
unknown but the patient died within two years after
diagnosis of a metastatic lesion have been censored as
previously described [16,17]. The surveillance period of
patients was variable and ranged from 3 days to 176
months, with a median of 86 months.
Statistical analysis
Pearson c
2 and Fisher’s exact test were used for catego-
rical variables where applicable. The outcome variables
analyzed were progression-free survival, cause-specific
survival and overall survival. Univariate analysis was
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mate survival and were compared using the log-rank
test [18]. Prognostic models used the Cox regression
analysis for multivariate analyses of survival in a forward
stepwise manner, as previously described [16,17,19].
Variables tested in this multivariate analysis were age at
surgery, FIGO stage, grading, lymphangiosis, myometrial
invasion, cervical involvement, ovarian metastasis, adju-
vant radiotherapy, occurrence of lymph node metastasis
and the performance of lymphadenectomy. Hazard
ratios (HR), 95% confidence intervals (CI) and p-values
are reported. Significance of differences was assumed at
p ≤ 0.05 at the two-sided tests (SPSS, version 15.0; SPSS
Inc., Munich, Germany).
Results
Clinical and pathological characteristics
The clinical and pathological characteristics of the
patients with endometrioid adenocarcinoma are sum-
marized in Table 1. Only patients (n = 214) with endo-
metrioid histology were included in this analysis. Mixed
and mucinous adenocarcinomas were also excluded
from analysis. The percentile distribution of stage I to
IV disease was comparable to the data provided in the
international literature [20], demonstrating the validity
of the patient group enrolled in this analysis. A lympha-
denectomy was performed in 151 (70.6%) of these
patients. Pathological investigation revealed that the
lymph nodes were positive for disease in 11 (5.1%) of
analysed cases. The median patient age at time of sur-
gery was 65.1 years (range 35.5-87.9). Lymphadenectomy
was performed in 90 (84.1%) patients younger than 65
years and 61 (57.0%) patients older than 65 years.
Most of the patients (n = 171 (79.9%) were diagnosed
at FIGO stage I (stage IA: 29 (13.6%), stage IB: 99
(46.3%), stage IC: 42 (20.1%)), and 120 (70.2%) patients
underwent lymphadenectomy. Of these patients, 81
(67.5%) presented with histological differentiation grade
I, 29 patients (24.2%) with grade II and 10 (8.4%) with
grade III. There was no difference in grading when com-
pared to the non-lymphadenectomy group. Thirty-three
patients (64.7%) showed a WHO histological grade 1,
while 15 patients (29.4%) and 3 patients (5.9%) showed
grade 2 and grade 3, respectively (p > 0.05).
Table 1 Clinical and pathological characteristics.
Total No Lymphadenectomy Lymphadenectomy p-Wert (Chi2)
Patient number n = 214 n = 63 (29.4%) n = 151 (70.6%)
Age at surgery >65 years 107 (50%) 46 (43.0%) 61 (57.0%) <0.001
≤65 years 107 (50%) 17 (15.9%) 90 (84.1%)
FIGO Stage I 171 (79.9%) 51 (29.8%) 120 (70.2%) N.S.
II 15 (7.0%) 6 (40.0%) 9 (60.0%)
III 21 (9.8%) 3 (14.3%) 18 (85.7%)
IV 7 (3.3%) 3 (42.9%) 4 (57.1%)
WHO Grade 1 134 (62.6%) 36 (26.9%) 98 (73.1%) N.S.
2 56 (26.2%) 18 (32.1%) 28 (67.9%)
3 24 (11.2%) 9 (37.5%) 15 (62.5%)
Lymphangiosis Negative 197 (92.1%) 57 (28.9%) 140 (71.1%) N.S.
Positive 17 (7.9%) 6 (35.3%) 11 (64.7%)
Deep myometrial invasion only endometrium 34 (15.9%) 9 (26.5%) 25 (73.5%) N.S.
<50% 111 (51.9%) 31 (27.9%) 80 (72.1%)
>50% 69 (32.2%) 23 (33.3%) 46 (66.7%)
Cervical involvement negative 191 (89.3%) 55 (28.8%) 136 (71.2%) N.S.
positive 23 (10.7%) 8 (34.8%) 15 (65.2%)
Ovarian metastasis negative 204 (95.2%) 61 (29.9%) 143 (70.1%) N.S.
positive 10 (4.7%) 2 (20%) 8 (80%)
Obesity Negative 137 (64.0%) 39 (28.5%) 98 (71.5%) N.S.
Positive 77 (36.0%) 24 (31.2%) 53 (68.8%)
Diabetes Negative 187 (87.4%) 49 (26.2%) 138 (73.8%) <0.05.
Positive 27 (12.6%) 14 (51.9%) 13 (48.1%)
Hypertension Negative 126 (58.49) 25 (19.8%) 101 (80.2%) <0.001.
Positive 88 (41.1%) 38 (43.2%) 50 (56.8%)
Adjuvant radiotherapy Not performed 138 (64.5%) 43 (31.2%) 95 (68.8%) N.S.
performed 76 (35.5%) 20 (26.2%) 56 (73.3%)
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(stage IIA: 2 (0.9%), stage IIB: 13 (6.12%)), and 60% of
these patients underwent lymphadenectomy. There were
21 (9.8%) patients with FIGO stage III cancer (stage
IIIA: 9 (4.2%), stage IIIB: 3 (1.4%) stage IIIC: 9 (4.2%)),
and the lymph nodes were removed in 85.7% of these
cases. The lymph nodes were positive for disease in all
the FIGO stage III patients, and these patients were
scaled to this stage after the operation, as suggested by
the FIGO classification system [3]. A lymphadenectomy
was performed in four out of the seven (3.3%) FIGO
stage IV patients.
One hundred and thirty four (62.6%) patients pre-
sented with a well-differentiated histology (WHO grade
1), and a lymphadenectomy was performed in 98
(73.1%) of these patients. The lymph nodes were
removed in 67.9% of the 56 (26.2%) patients with a
grade of moderate differentiation. The number of
patients with poorly-differentiated histology was 24
(11.2%), and 62.5% of these patients underwent
lymphadenectomy.
Seventeen of the 214 analyzed patients had a lym-
phangiosis, and six patients exhibited a haemangiosis.
The frequency of lymphadenectomy was slightly lower
in patients with lymphangiosis (64.7%) or haemangiosis
(66.7%) compared to patients without (71.1% and
70.7%).
Obesity was observed in 77 (36.0%) cases. Although
lymphadenectomy is more difficult in obese patients,
the frequency of lymphadenectomy in these patients
(68.8%) was in fact similar to that in non-obese
patients (71.5%). Of the 214 patients, 76 (35.5%)
received adjuvant radiotherapy. The lymph nodes were
removed in 73.3% of these patients, compared to 68.8%
in patients without adjuvant radiotherapy. Anti-hormo-
nal therapy was administered to seven (3.3%) patients,
and a lymphadenectomy was performed in three of
these patients. Among the factors examined for asso-
ciation with lymphadenectomy, significant differences
were found only for age, diabetes and hypertension
(Table 1).
Survival analyses
Recurrence or progression was observed in 29 (13.6%)
patients, while 62 (29.0%) patients died during follow-
up, and 25 (11.68%) patients died as a result of the
endometrial cancer. The median follow-up time for all
uncensored patients was 98.7 months (range 0.3-176.8
months), and the median time to death in the uncen-
sored subgroup was 55.3 months (range 0.72-143.0
months).
Although the frequency of lymphadenectomy was
higher in patients who did not suffer a recurrence of the
cancer (71.9%, versus 62.1% in patients who did suffer a
recurrence) and the progression-free survival curve
showed a tendency to increased survival for patients
who underwent lymphadenectomy, the results were not
statistically significant for patients in the early stage
(FIGO I), or for all stages (Figures 1 and 2). However, a
significant prognostic benefit in terms of increased
cause-specific survival was observed for patients who
had their lymph nodes removed, for patients in early-
stage (FIGO I), and for all stages (Figures 3 and 4). The
overall survival curve for all analysed cases also showed
a significant prognostic impact of lymphadenectomy
(p =< 0.001) (Figures 5 and 6).
Multivariate Cox regression analysis
Multivariate Cox regression analysis was performed to
evaluate lymphadenectomy as an independent prognos-
tic marker in patients with endometrioid adenocarci-
noma (Table 2). The following well known parameters
influencing survival were included: age, FIGO stage,
WHO grading, cervical involvement, deep myometrial
invasion, ovarian metastasis, presence of positive nodes,
and adjuvant radiotherapy. For overall survival, a signifi-
cant effect was observed for age (p < 0.001), FIGO stage
(p = 0.002), grading (p = 0.016), cervical involvement
(p < 0.001) and lymphadenectomy (p =0 . 0 0 1 ) .C a u s e -
specific survival was influenced by FIGO stage (p =
0.006), cervical involvement (p = 0.010), deep myometrial
invasion (p = 0.019) and lymphadenectomy (p = 0.005).
For progression-free survival, FIGO stage (p < 0.001),
grading (p = 0.041), cervical involvement (p =0 . 0 1 9 )a n d
Figure 1 Progression-free survival. Kaplan-Meier curve of clinical
outcome for progression-free survival demonstrates no significant
difference arising from lymphadenectomy for patients at FIGO stage
I (A), or all stages (B). Follow-up time is defined as the time until
progression occurred.
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factors.
Conclusions
Endometrial cancer is the most common female pelvic
malignancy in the western world. Endometrioid histol-
ogy is thought to be a low-risk histology with a very
good prognosis, especially if diagnosed early [15]. The
five-year survival rate is dependent on stage, and is 87-
93% for grade 1 and 2 and approximately 61% for
poorly-differentiated endometrioid adenocarcinomas. In
contrast, the five-year survival rate for clear-cell adeno-
carcinoma is approximately 42%, and only 24-34% for
cases of serous-papillary histology [21].
Staging and therapeutic surgical intervention includes
an explorative laparatomy with radical hysterectomy and
bilateral salpingo-oophorectomy, peritoneal washing,
and pelvic and para-aortic lymph node sampling [3].
However, no specifications regarding the type, extent
and prognostic impact of pelvic lymph node dissection
Figure 2 Cause-specific survival. Kaplan-Meier curve of clinical
outcome for cause-specific survival demonstrates a significant
impact on patients treated with lymphadenectomy (log-rank: p=
0.044) at early FIGO stage (A) and all stages (B). Follow-up time is
defined as the time until cause-specific death occurred.
Figure 3 Overall survival. Kaplan-Meier curve of clinical outcome
for overall survival demonstrates a significant impact on patients
treated with lymphadenectomy for FIGO stage I patients (A) and all
stages (B) (log-rank: p < 0.001). Follow-up time is defined as the
time until death occurred.
Figure 4 Cause-specific survival for patients at all stages.
Kaplan-Meier curve of clinical outcome for cause-specific survival
demonstrates a significant impact on patients treated with
lymphadenectomy (log-rank: p=0.044) at all stages. Follow-up time
is defined as the time until cause-specific death occurred.
Figure 5 Overall survival for patients at FIGO stage I.K a p l a n -
Meier curve of clinical outcome for overall survival demonstrates a
significant impact on patients treated with lymphadenectomy for
FIGO stage I patients (log-rank: p<0.001). Follow-up time is defined
as the time until death occurred.
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ongoing debate.
In 1995, Kilgore and colleagues published a retrospec-
tive analysis of 649 patients with adenocarcinoma of the
endometrium. Of these patients, 212 underwent multi-
ple-side lymph node sampling and 205 patients had lim-
ited pelvic node sampling (less than four pelvic sites),
while 208 patients were not sampled. Overall survival
was significantly better in patients with multiple-site
lymph node sampling. Adjuvant radiation or splitting
into low- and high-risk groups did not affect this result
[7].
In a 2007 analysis of the large SEER database from the
United States, 42,814 patients with endometrial adeno-
carcinoma were analysed by multivariate Cox regression
analysis [13], and the rate of lymphadenectomy was
found to be only 46%. Lymphadenectomy was identified
as an independent prognostic factor for overall survival,
with hazard ratios of 0.74 for the subgroup with more
than 11 lymph nodes dissected, and 0.89 for the sub-
group with 1-11 nodes removed [13].
Although a very small number of studies have not
shown that lymphadenectomy has an impact on survival
[9], most studies have demonstrated increased survival
and have established lymphadenectomy as an important
prognostic factor. This is also supported by the results
of a few authors who have detected an increasing fre-
quency of lymphadenectomy in recent decades. For
example, in a retrospective analysis of 1,312 patients,
Barakat et al. demonstrated an increase from 28% in
1993 to 82% in 2004 [22]. For patients of the SEER pro-
gram, the frequency has risen from 31% in 1988 to 53%
in 2003 [13].
However, the relevance of overall survival is limited,
because compared to other patients, the frequency of
lymphadenectomy is low in older patients with comor-
bidities. For this reason, analysis of progression-free sur-
vival is a more meaningful approach. In our study, the
results from the progression-free survival curve are not
statistically significant. However, the results from multi-
variate analysis (p = 0.016) argue that lymphadenectomy
d o e sh a v eam a j o ri n f l u e n c eo np r o g r e s s i o n - f r e es u r v i -
val. Since patients with FIGO stage I also did not show
increased survival, we assume that the usefulness of
lymphadenectomy as an independent prognostic factor
results from increased survival of patients in higher
stages. In this study, the number of patients with grade
3 (11.2%) or higher (13.1%) FIGO stage cancer is very
low, so it is not possible to perform adequate statistical
analysis of survival. Nevertheless, we were able to
demonstrate that lymphadenectomy had an impact on
cause-specific and overall survival of patients with endo-
metrioid histology, for patients of early-stage, and all
stages.
The question of whether pelvic lymphadenectomy
improves survival rates of high-risk patients has not yet
been resolved. Lutman et al. demonstrated improved
overall and progression-free survival in a group of
patients with FIGO stage 1-2, high-risk histology (clear-
cell, papillary serous or grade 3 endometrioid histology)
and more than 12 lymph nodes dissected. For low-risk
cases, the results were not significant [11]. Similarly, in
another study no significant impact on overall survival
was demonstrated for low risk-patients (grade 1 and 2,
Figure 6 Overall survival for patients at all stages. Kaplan-Meier
curve of clinical outcome for overall survival demonstrates a
significant impact on patients treated with lymphadenectomy for all
stages (log-rank: p<0.001). Follow-up time is defined as the time
until death occurred.
Table 2 Hazard ratios by multivariate Cox regression analysis.
Progression-free survival Cause-specific survival Overall survival
HR CI (5-95%) p HR CI (5-95%) p HR CI (5-95%) p
Age (>65 years) - - - - - - 3.779 2.006 - 7.118 <0.001
WHO Grading (G 1/2 vs. G 3) 2.631 1.038 - 6.667 0.041 - - - 2.214 1.158 - 4.231 0.016
FIGO Stage (1/2 vs. 3/4) 7.827 3.176 - 19.288 <0.001 3.870 1.461 - 10.254 0.006 2.874 1.460 - 5.655 0.002
Cervical involvement 2.861 1.190 - 6.878 0.019 3.403 1.333 - 8.690 0.010 3.456 1.742 - 6.856 <0.001
Deep myometrial invasion 3.172 1.461 - 10.254 0.019
Performed Lymphadenectomy 0.376 0.162 - 0.871 0.022 0.308 0.134 - 0.706 0.005 0.403 0.234 - 0.695 0.001
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clear-cell differentiation) [12]. Further, in a recent pro-
spective study, there was no evidence of benefit in terms
of overall or recurrence-free survival arising from pelvic
lymphadenectomy in women with early endometrial
cancer [14].
A contribution to the survival of patients who undergo
lymphadenectomy may be the identification of patients
with nodes positive for disease, a significant prognostic
parameter [5], and the administration of a suitable adju-
vant therapy. However, the incidence of cases with
nodal metastases is very low, which suggests that lym-
phadenectomy itself has a therapeutic benefit. A final
possible explanation is the removal of occult small
metastatic disease which was not detected by classical
histopathological evaluation [23,24].
There is a small number of unsolved issues. The
extent of the lymphadenectomy would have a major
impact on the benefit to patient survival, meaning that
as more lymph nodes were removed, the probability
would increase of identifying patients with nodes posi-
tive for disease. Also, the therapeutic effect of remov-
ing occult lymph node metastases would rise. For this
analysis, we disregarded the extent and localisation of
the removed lymph nodes. In the literature, the cut-off
for splitting patients undergoing lymphadenectomy
into a limited sampling and a multiple sampling group
is around 10 to 12 lymph nodes. Although this number
is essentially the median, it is basically a randomly-
selected range, and exceeding the cut-off does not
mean that a full dissection will be made. Of course,
the regions sampled also play a decisive role in the
patients’ outcome. An impact on survival of para-aortic
sampling in patients with high-risk adenocarcinoma of
the endometrium was demonstrated by Chang and col-
leagues [25]. However, it is not yet known whether
para-aortic lymph node dissection could play a sub-
stantial role in routine treatment of all patients.
Furthermore the possibility of underestimating FIGO
IIIC disease in non-surgically-staged patients remains,
and this problem cannot be solved by any current ima-
ging modality.
The main purpose of this analysis was to investigate
the effect of lymphadenectomy only in patients with
endometrioid histology. Our results show that lympha-
denectomy improves patient survival, and so demon-
strate the prognostic relevance of this intervention in
treatment of patients with endometrioid adenocarci-
noma. Therefore, a pelvic and/or para-aortal lymphade-
nectomy should be performed during surgery, even in
endometrioid adenocarcinoma. In a recent prospective
study, there was no evidence of benefit in terms of over-
all or recurrence-free survival from pelvic lymphade-
nectomy in women with early endometrial cancer [14].
However, these results remain to be confirmed in
further studies.
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